A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study

BACKGROUND: Combined treatment with cisplatin and gemcitabine (CisGem) is the standard of care for patients with advanced biliary tract cancer (ABC). Selumetinib (AZD6244, ARRY-142886) potently and selectively inhibits MEK1/2, an intracellular kinase and has shown activity in ABC. The objective of t...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Cancer
Hlavní autoři: Bridgewater, John, Lopes, Andre, Beare, Sandra, Duggan, Marian, Lee, Dymphna, Ricamara, Maravic, McEntee, Delyth, Sukumaran, Ajithkumar, Wasan, Harpreet, Valle, Juan W.
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2016
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4766710/
https://ncbi.nlm.nih.gov/pubmed/26912134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2174-8
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky